Citigroup maintained Thermo Fisher Scientific (NYSE: TMO ) with a Buy rating and lowered the price target from $83.00 to $82.00. Citigroup noted, "TMO delivered the 4th strong quarter of the year beating on both the top and bottom line driven by strength in Biopharma (similar with WAT) and Healthcare